Advocating for Health Equity

Shaping a new era of global health investment, policy, planning and prevention

AVAC Meeting in NYC

Advocacy and activism have been a linchpin in the history of HIV treatment and prevention. The visionary work of passionate advocates has resulted in hard-fought global gains against HIV.

AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.

Our advocacy takes place:

  • Where funders, policies and programs come together.
  • At the point of service delivery, where options from the pipeline must become choices in people’s lives. 
  • At Parliaments, State Houses, Ministries of Health, National legislatures, and international bodies,to press for global and country accountability.
  • In the hands of robust and sophisticated coalitions of African-led civil society organizations.

Upcoming Events & Webinars

African Workshop on HIV & Women 2025

Meeting

Read More

Conference on Retroviruses and Opportunistic Infections 2025

Meeting

Read More

What's New

report

Worldwide Prevention, Shared Protection

This Issue Brief describes the impacts of the elimination and reduction of funding that supports sexually transmitted infection (STI) research, testing, and prevention programming. This funding is critically important as STI rates continue to increase globally with more than 1 million curable STIs, including chlamydia, gonorrhea, syphilis, and trichomoniasis, acquired every day. Without appropriate testing, treatment, and prevention programs, there is a risk that STI rates will continue to increase leading to more cases of infertility, pelvic inflammatory disease, and cancers.

STIs
Read more

podcast

Lawsuit Wins and What's at Stake

On February 10, AVAC led other organizations to sue  the US government including the President, the US State Department and USAID,  seeking emergency relief from an Executive Order that inhumanely froze all funding for foreign assistance. This case may well help to determine the future of foreign assistance, executive overreach, and the role of evidence, facts, and values in US policy. AVAC’s Executive Director, Mitchell Warren and Public Citizen Litigator, Lauren Bateman explain these lawsuits and why they matter.

Read more

LEN Generics — Can we go faster?

The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.

Use this infographic:

Embed Download PDF Download Image
See more infographics

Related Projects

The Latest on Advocating for Health Equity

Report

Worldwide Prevention, Shared Protection

This Issue Brief describes the impacts of the elimination and reduction of funding that supports sexually transmitted infection (STI) research, testing, and prevention programming. This funding is critically important as STI rates continue to increase globally with more than 1 million curable STIs, including chlamydia, gonorrhea, syphilis, and trichomoniasis, acquired every day. Without appropriate testing, treatment, and prevention programs, there is a risk that STI rates will continue to increase leading to more cases of infertility, pelvic inflammatory disease, and cancers.

Article

Research Matters – Resources to Protect Research Funding 

For more than 30 years, AVAC and partners have worked to protect the infrastructure and funding that drives lifesaving HIV and biomedical research. Today, that mission is more urgent than ever. Funding from the National Institutes of Health (NIH) fuels innovation, drives the economy, and saves lives. Cuts to this support will make America—and the world—poorer, sicker, and less prepared for future health threats.

Article

AVAC and FAPP Written Statement: US Senate Hearing on Biomedical Research

AVAC and GAPP submitted written testimony for the US Senate Appropriations Subcommittee’s April 30th hearing, “Biomedical Research: Keeping America’s Edge in Innovation.”